Pages that link to "Q1181878"
Jump to navigation
Jump to search
The following pages link to decitabine (Q1181878):
Displaying 50 items.
- acute myeloid leukemia (Q264118) (← links)
- myelodysplastic syndrome (Q954625) (← links)
- DNA methyltransferase 1 (Q5205796) (← links)
- DNA methyltransferase 3 alpha (Q22680017) (← links)
- The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer (Q26766285) (← links)
- DNMT3A Mutation (Q28444963) (← links)
- DNMT1 EXPRESSION (Q28445036) (← links)
- KRAS Mutation (Q28445037) (← links)
- Dacogen (Q29005690) (← links)
- Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment. (Q34676418) (← links)
- Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice (Q46156118) (← links)
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies (Q61894499) (← links)
- Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia (Q61917893) (← links)
- Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML) (Q61936355) (← links)
- PRO#0118: Decitabine Plus Mini Flu-Bu (Q61966137) (← links)
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA (Q61969843) (← links)
- Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia (Q61980876) (← links)
- Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia (Q61981015) (← links)
- A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (Q61981363) (← links)
- Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies (Q62031276) (← links)
- Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer (Q62042245) (← links)
- Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia (Q62054404) (← links)
- Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients (Q62055048) (← links)
- Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation (Q62062127) (← links)
- Quizartinib and Decitabine in Treating Participants With Untreated or Relapsed FLT3-ITD Mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome (Q62062313) (← links)
- Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders (Q62104879) (← links)
- Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure (Q62104974) (← links)
- Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (Q62105325) (← links)
- Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas (Q62110092) (← links)
- Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia (Q62110199) (← links)
- Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia (Q62110200) (← links)
- Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 (Q62110698) (← links)
- Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer (Q62110714) (← links)
- Safety and Efficacy Evaluation of Decitabine With R-GDP (Q62814386) (← links)
- The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer (Q63011860) (← links)
- Cytarabine, Idarubicin, Liposome-encapsulated Daunorubicin-Cytarabine or Decitabine in Treating Older Patients With Acute Myeloid Leukemia (Q63013620) (← links)
- An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS) (Q63062316) (← links)
- Decitabine, Cytarabine, GCSF for Refractory AML/MDS (Q63062844) (← links)
- Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (Q63229434) (← links)
- STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy (Q63229649) (← links)
- Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia (Q63229716) (← links)
- Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (Q63316975) (← links)
- Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (Q63318133) (← links)
- Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia (Q63322187) (← links)
- Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS (Q63322749) (← links)
- Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) (Q63334146) (← links)
- Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients (Q63336848) (← links)
- Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (Q63340235) (← links)
- Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT (Q63394457) (← links)
- A Phase 1b/2 Study of Alvocidib Plus Decitabine in Patients With MDS (Q63394928) (← links)